🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

📣Are you interested in leading an organisation with the mission of advocating for HIV patients? EATG is hiring a new Executive Director! EATG represents a network of more than 150 members, from 45 countries in Europe. Apply below! 👉bit.ly/3QABIfi

Congratulations to our colleagues at KU Leuven, who will present a poster today at ISPOR 2023 on the work MPE and our Israeli member AMEN have been supporting on shared decision making. ispor.org/heor-resources…

Participate in our myeloma survey on shared decision-making! Share your experiences to improve communication between patients and healthcare professionals. Available in English, Hebrew, Slovenian, German, Spanish, French, Dutch, and Swedish mpeurope.org/patient-eviden…

The brilliant Samantha Nier (She/Her) highlighting results of Acute Leukemia Advocates Network (ALAN) #carer survey and the unmet needs for support. #ASH2023 Pfizer Inc. #advocacybreakfast

The European Commission grants final approval for elranatamab for the treatment of relapsed or refractory #myeloma mpeurope.org/2023/12/08/the…

#ASH23 has already started for the MPE team! Ready to learn about the more important updates on #myeloma and #ALamyloidosis and meet friends and colleagues

Great to see so many patient advocates presenting relevant research at the #ASH23 poster sessions. Congratulations! 1/1 Myeloma UK Acute Leukemia Advocates Network (ALAN)

MPE is a partner in an exciting new Horizon Europe 🇪🇺 project called #CERTAINTY, which explores the role of virtual twins in CAR-T and personalised #myeloma care. You can explore further information about the project here:

EU Medicines Agency CHMP confirms recommendation for non-renewal of Blenrep marketing authorisation. Read more about it here: mpeurope.org/2023/12/15/ema…

Led by @EHA_hematology, with the involvement of MPE, the article "Guidelines for the Use and Reporting of Patient-Reported Outcomes in Multiple Myeloma Clinical Trials" is now published! An important step in improving the collection of #PROs. mdpi.com/2072-6694/15/2…

EU funded project ASCERTAIN , of which MPE is a partner, is in its second year! The Consortium meeting ended yesterday with presentations on the project’s progress, followed by discussions and suggestions from partners and advisory board members access2meds.eu/about-ascertai…

Commissioner Stella Kyriakides highlights #EUCancerPlan progress, including the first EU network linking National Comprehensive Cancer Centres in every MS, but discussions show more work remains to tackle inequalities, among other issues. #WorldCancerDay

.EU Medicines Agency CHMP gives positive recommendation on #CART-cell therapy ciltacabtagene autoleucel in earlier lines of therapy for relapsed and refractory #myeloma mpeurope.org/2024/02/23/ema…

BREAKING: U.S. FDA’s ODAC Recognizes MRD as an Accepted End Point for Accelerated Approval in Multiple Myeloma #mmsm #oncology onclive.com/view/fda-s-oda…

Today, US FDA held an ODAC meeting to debate MRD as an endpoint to support accelerated approval in #myeloma clinical trials. Two groups (Sylvester Comprehensive Cancer Center and i2TEAMM) presented retrospective data from clinical trials that measured MRD. Final vote was 12-0 in favor.

ODAC unanimously votes in favor of using #MRD as an early endpoint for accelerated approval in #myeloma trials This was a huge team effort for more than 8 years and with the generosity of unprecedented data sharing from many investigators around the world. Thank you all! #mmsm

U.S. FDA's Oncologic Drugs Advisory Committee (ODAC) recognises Minimal Residual Disease (MRD) as an accepted endpoint for accelerated approval in myeloma. Read more information here: onclive.com/view/fda-s-oda… OncLive.com #myeloma #MRD

MPE Co-CEO, Katie Joyner, spoke at EMN's 5th annual meeting, highlighting the importance of empowering European patients to access clinical trial information. ¨Patients deserve accurate, comprehensive information for informed discussions with healthcare teams.¨

We are looking for a new consultant colleague (10 PA, substantive NHS post). Great opportunity for anyone with an interest in myeloma who wants to join an academic centre. royalmarsden.nhs.uk/current-vacanc…

We asked patients, carers, clinicians, researchers and stakeholders about the biggest challenges in #myeloma and how MPE can make a difference. Their insights helped shape our new Strategic Goals 2025 – 2030. These will drive our work in the coming years. mpeurope.org/about-mpe/our-…